Neoadjuvant therapy in breast cancer – objectives and tasks
DOI:
https://doi.org/10.15584/ejcem.2019.2.8Keywords:
neoadjuvant therapy (NCT), breast cancer (BC), triple negative breast cancer (TNBC)Abstract
Introduction. Neoadiuvant therapy (NCT) in the treatment of breast cancer is employed for patients with early stage disease or with inoperable disease. NCT can decrease the tumor volume. It can facilitate breast conservation therapy. Response to NCT is a strong predictor of outcome breast cancer (BC). Direct target therapies has markedly improved the result of treatment BC.
Aim. Therapy for breast cancer continues to improve. The importance of tumor burden on local control rates will be in the future.
Material and methods. This analysis was performed using a systematic literature search.
Results. The latest scientific reports give hope for greater safety and a better life for patients based on optimized and effective therapy.
Conclusion. Currently, improving the effectiveness of breast cancer treatment is mainly related to the optimal use of classic therapeutic strategies. New classes of substances have been approved for treatment or are in advanced stages of clinical development.
Downloads
References
Conlin AK, Seidman AD. Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Mol Diagn Ther. 2007;11(6):355-360.
Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(3):141-145.
Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do I use neoadjuvant chemotherapy for breast cancer? Curr Treat Options Oncol. 2014;15(1):86-98.
Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 ;40(2):476-482.
Sueta A, Yamamoto Y, Hayashi M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? Surgery. 2014;155(5):927-935.
Benson JR, Jatoi I. patie Sentinel lymph node biopsy and neoadjuvant chemotherapy in breast cancernts. Future Oncol. 2014;10(4):577-586.
Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115103.
Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015; 27;17:11.
Yuan H, Chen J, Liu Y, et al. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer. Clin Cancer Res. 2015; 1;21(19):4365-4372.
Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015; 6(5-6):206-213.
Hylton NM, Gatsonis CA, Rosen MA, et al. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016;279(1):44-55.
Hurvitz S, Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016;28(1):59-69.
Lo WC, Li W, Jones EF, et al. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016;11(2):e0142047.
Ma CX, Bose R, Ellis MJ. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. Adv Exp Med Biol. 2016;882:125-154.
Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87-96.
Fuss TL, Cheng LL. Evaluation of Cancer Metabolomics Using ex vivo High Resolution Magic Angle Spinning (HRMAS) Magnetic Resonance Spectroscopy (MRS). Metabolites. 2016;22;6(1). pii: E11.
Rampulwala M, Wisinski KB, O'Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol. 2016;14(3):186-193.
Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist. 2016;21(9):1050-1062.
Yeung C, Hilton J, Clemons M, et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Cancer Metastasis Rev. 2016;35(3):427-437.
Bufi E, Belli P, Di Matteo M, et al. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer. Clin Breast Cancer. 2016 ;16(6):e193-e201.
Soran A, Bhargava R, Johnson R, et al. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Dis. 2016; 36(2-3):65-71.
Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913-1924.
Mistry DA, French PW. Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl). 2016;13;10:191-196.
Tanino H, Kosaka Y, Nishimiya H, et al. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. PLoS One. 2016; 9;11(12):e0165721.
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017; 389(10087):2430-2442.
Luen SJ, Salgado R, Fox S, et al. analysis of t he CLTumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective CLEOPATRA study. Lancet Oncol. 2017;18(1):52-62.
Chen X, He C, Han D, Zhou M, Wang Q, Tian J, Li L, Xu F, Zhou E, Yang K. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(9):843-857.
Li L, Han D, Wang X, et al. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(11):1021-1034.
Petrovic N, Davidovic R, Bajic V, Obradovic M, Isenovic RE. MicroRNA in breast cancer: The association with BRCA1/2. Cancer Biomark. 2017;19(2):119-128.
Wuerstlein R, Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Rev Recent Clin Trials. 2017;12(2):81-92.
Ramteke P, Seenu V, Prashad R, et al. Alteration in n losteroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy ically advanced breast cancer: Experience at a tertiary care centre in India. Indian J Cancer. 2016;53(3):366-371.
Haukaas TH, Euceda LR, Giskeødegård GF, Bathen TF. Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. Metabolites. 2017;16;7(2). pii: E18.
Solinas C, Ceppi M, Lambertini M, et al. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treat Rev. 2017;57:8-15.
Jagannathan NR, Sharma U. Breast Tissue Metabolism by Magnetic Resonance Spectroscopy. Metabolites. 2017; 7;7(2). pii: E25.
Harbeck N, Gluz O. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast. 2017;34 Suppl 1:99-103.
Schlotter CM, Tietze L, Vogt U, Heinsen CV, Hahn A. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. Horm Mol Biol Clin Investig. 2017;22,32(2).
Xu Y, Ouyang T, Li J, et al. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci. 2018 ;109(1):166-173.
Blok EJ, Bastiaannet E, van den Hout WB, et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev. 2018; 62:74-90.
Li X, Dai D, Chen B, Tang H, Wei W. Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. World J Surg Oncol. 2017;28,15(1):210.
Thompson TC, Li L, Broom BM. Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness. Oncotarget. 2017; 8(55):93315-93316.
Okuma HS, Yonemori K. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Adv Exp Med Biol. 2017;1026:271-286.
Siow ZR, De Boer RH, Lindeman GJ, Mann GB. Spotlight on the utility of the Oncotype DX(®) breast cancer assay. Int J Womens Health. 2018; 21;10:89-100.
Rauch GM, Adrada BE. Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation. Magn Reson Imaging Clin N Am. 2018;26(2):273-280.
Henderson SA, Muhammad Gowdh N, Purdie CA, et al. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. Br J Radiol. 2018;91(1087):20180123.
Vieira AF, Schmitt F. An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers. Front Med (Lausanne). 2018;5:248.
Hwang KT, Han W, Lee SM, Choi J, Kim J, Rhu J, Kim YA, Noh DY. Prognostic influence of 3-dimensional tumor volume on breast cancer compared to conventional 1-dimensional tumor size. Ann Surg Treat Res. 2018 ;95(4):183-191.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
